Cargando…
Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo
BACKGROUND: Atopic dermatitis (AD) is a complex inflammatory skin condition characterized by the proliferation and activation of immune cells in skin. Isoliquiritin (ISO) is an active component purified from Glycyrrhiza glabra. This study aimed to test the therapeutic potential of ISO for AD and ver...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577790/ https://www.ncbi.nlm.nih.gov/pubmed/36267759 http://dx.doi.org/10.21037/atm-22-3989 |
_version_ | 1784811838223941632 |
---|---|
author | Wu, Qing Mo, Xiumei Lin, Ying Liu, Junfeng Ye, Siqi Zhang, Yu Fan, Xingxing Chen, Dacan Yan, Fenggen |
author_facet | Wu, Qing Mo, Xiumei Lin, Ying Liu, Junfeng Ye, Siqi Zhang, Yu Fan, Xingxing Chen, Dacan Yan, Fenggen |
author_sort | Wu, Qing |
collection | PubMed |
description | BACKGROUND: Atopic dermatitis (AD) is a complex inflammatory skin condition characterized by the proliferation and activation of immune cells in skin. Isoliquiritin (ISO) is an active component purified from Glycyrrhiza glabra. This study aimed to test the therapeutic potential of ISO for AD and verify its potential molecular mechanism. METHODS: This study investigated the potential effects and possible underlying mechanisms of ISO against AD in vitro (HMC1.1 cells stimulated by phorbol-12-myristate-13-acetate and calcium ionophore A23187) and in vivo (AD-like mouse model induced by 1-chloro-2,4-dinitrochlorobenzene). RESULTS: ISO dose-dependently suppressed the viability of HMC1.1 cells. ISO inhibited the secretion of the proinflammatory factors IL-6 and IL-8 and induced the apoptosis of HMC1.1 cells. ISO suppressed the phosphorylation of CD177, JAK2, STAT1, STAT3, and STAT5, and upregulated the protein expression of BAX and cleaved caspase-3 in vitro. ISO administration markedly diminished the infiltration of immune cells (mast cells, eosinophils) in cutaneous lesions. Simultaneously, ISO treatment alleviated the formation of skin lesions and affected other AD symptoms (thickness of the epidermis and dermis, ear edema, lymph node weight, spleen index, dermatitis score) but increased the thymus index in vivo, and downregulated expression of IL-4, IL-6, IgE, and thymic stromal lymphopoietin (TSLP). CONCLUSIONS: Collectively, our findings showed that ISO administration decreased skin lesion formation by inhibiting inflammation and enhancing immunomodulation through the CD177/JAK2/STAT signaling pathway. |
format | Online Article Text |
id | pubmed-9577790 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-95777902022-10-19 Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo Wu, Qing Mo, Xiumei Lin, Ying Liu, Junfeng Ye, Siqi Zhang, Yu Fan, Xingxing Chen, Dacan Yan, Fenggen Ann Transl Med Original Article BACKGROUND: Atopic dermatitis (AD) is a complex inflammatory skin condition characterized by the proliferation and activation of immune cells in skin. Isoliquiritin (ISO) is an active component purified from Glycyrrhiza glabra. This study aimed to test the therapeutic potential of ISO for AD and verify its potential molecular mechanism. METHODS: This study investigated the potential effects and possible underlying mechanisms of ISO against AD in vitro (HMC1.1 cells stimulated by phorbol-12-myristate-13-acetate and calcium ionophore A23187) and in vivo (AD-like mouse model induced by 1-chloro-2,4-dinitrochlorobenzene). RESULTS: ISO dose-dependently suppressed the viability of HMC1.1 cells. ISO inhibited the secretion of the proinflammatory factors IL-6 and IL-8 and induced the apoptosis of HMC1.1 cells. ISO suppressed the phosphorylation of CD177, JAK2, STAT1, STAT3, and STAT5, and upregulated the protein expression of BAX and cleaved caspase-3 in vitro. ISO administration markedly diminished the infiltration of immune cells (mast cells, eosinophils) in cutaneous lesions. Simultaneously, ISO treatment alleviated the formation of skin lesions and affected other AD symptoms (thickness of the epidermis and dermis, ear edema, lymph node weight, spleen index, dermatitis score) but increased the thymus index in vivo, and downregulated expression of IL-4, IL-6, IgE, and thymic stromal lymphopoietin (TSLP). CONCLUSIONS: Collectively, our findings showed that ISO administration decreased skin lesion formation by inhibiting inflammation and enhancing immunomodulation through the CD177/JAK2/STAT signaling pathway. AME Publishing Company 2022-09 /pmc/articles/PMC9577790/ /pubmed/36267759 http://dx.doi.org/10.21037/atm-22-3989 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Wu, Qing Mo, Xiumei Lin, Ying Liu, Junfeng Ye, Siqi Zhang, Yu Fan, Xingxing Chen, Dacan Yan, Fenggen Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo |
title | Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo |
title_full | Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo |
title_fullStr | Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo |
title_full_unstemmed | Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo |
title_short | Inhibitory effects of isoliquiritin on an atopic dermatitis model through the CD177/JAK2/STAT pathway in vitro and in vivo |
title_sort | inhibitory effects of isoliquiritin on an atopic dermatitis model through the cd177/jak2/stat pathway in vitro and in vivo |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577790/ https://www.ncbi.nlm.nih.gov/pubmed/36267759 http://dx.doi.org/10.21037/atm-22-3989 |
work_keys_str_mv | AT wuqing inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo AT moxiumei inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo AT linying inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo AT liujunfeng inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo AT yesiqi inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo AT zhangyu inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo AT fanxingxing inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo AT chendacan inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo AT yanfenggen inhibitoryeffectsofisoliquiritinonanatopicdermatitismodelthroughthecd177jak2statpathwayinvitroandinvivo |